Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemotherapy with Immunotherapy Induction in TNBC
NCT04373031Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Jul 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of citoplurikin in triple-negative breast cancer (TNBC) (2 arms). Primary endpoint: Pathological Complete Response Rate at 9 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
citoplurikin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04373031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373031.